Lichen China (LICN) Competitors

$1.33
-0.05 (-3.62%)
(As of 05/1/2024 ET)

LICN vs. AINC, ROMA, PNBK, XIN, GLBZ, NYC, MCVT, SFES, BENF, and MEGL

Should you be buying Lichen China stock or one of its competitors? The main competitors of Lichen China include Ashford (AINC), Roma Green Finance (ROMA), Patriot National Bancorp (PNBK), Xinyuan Real Estate (XIN), Glen Burnie Bancorp (GLBZ), American Strategic Investment (NYC), Mill City Ventures III (MCVT), Safeguard Scientifics (SFES), Beneficient (BENF), and Magic Empire Global (MEGL). These companies are all part of the "finance" sector.

Lichen China vs.

Ashford (NYSE:AINC) and Lichen China (NASDAQ:LICN) are both small-cap finance companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, earnings, dividends, community ranking, profitability, institutional ownership, risk, analyst recommendations and valuation.

Lichen China has a net margin of 0.00% compared to Lichen China's net margin of -0.60%. Ashford's return on equity of 0.00% beat Lichen China's return on equity.

Company Net Margins Return on Equity Return on Assets
Ashford-0.60% -17.01% 10.18%
Lichen China N/A N/A N/A

Ashford received 4 more outperform votes than Lichen China when rated by MarketBeat users.

CompanyUnderperformOutperform
AshfordOutperform Votes
4
100.00%
Underperform Votes
No Votes
Lichen ChinaN/AN/A

In the previous week, Ashford and Ashford both had 1 articles in the media. Lichen China's average media sentiment score of 0.00 beat Ashford's score of -0.59 indicating that Ashford is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ashford
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Lichen China
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Negative

13.3% of Ashford shares are owned by institutional investors. 60.4% of Ashford shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Lichen China has lower revenue, but higher earnings than Ashford.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ashford$765.86M0.02-$4.63M-$13.38-0.36
Lichen China$39.76M0.89$8.34MN/AN/A

Ashford has a beta of 1.64, meaning that its share price is 64% more volatile than the S&P 500. Comparatively, Lichen China has a beta of -2.68, meaning that its share price is 368% less volatile than the S&P 500.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ashford
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Lichen China
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Summary

Ashford beats Lichen China on 7 of the 11 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LICN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LICN vs. The Competition

MetricLichen ChinaManagement consulting services IndustryFinance SectorNASDAQ Exchange
Market Cap$36.57M$2.80B$8.68B$7.46B
Dividend YieldN/A2.62%10.66%3.97%
P/E RatioN/A11.6959.0216.50
Price / Sales0.8937.053,664.4688.52
Price / Cash3.2720.7028.2035.84
Price / Book0.573.612.294.27
Net Income$8.34M$127.81M$1.02B$214.24M
7 Day Performance20.91%0.54%-0.02%1.20%
1 Month Performance30.39%-6.42%-1.36%-3.86%
1 Year Performance-52.50%9.43%13.72%8.19%

Lichen China Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AINC
Ashford
0 of 5 stars
$4.78
-0.6%
N/AN/A$16.50M$746.80M-0.36N/AUpcoming Earnings
Positive News
ROMA
Roma Green Finance
0 of 5 stars
$0.72
-1.4%
N/AN/A$7.54MN/A0.0016
PNBK
Patriot National Bancorp
0 of 5 stars
$3.70
+2.8%
N/A-55.3%$14.73M$64.96M-4.25130Gap Up
XIN
Xinyuan Real Estate
0 of 5 stars
$2.71
+0.4%
N/A-29.1%$14.63M$950.01M0.001,160Analyst Report
News Coverage
Gap Down
GLBZ
Glen Burnie Bancorp
3.0854 of 5 stars
$5.06
-2.9%
N/A-30.2%$14.62M$14.44M10.1289Upcoming Earnings
NYC
American Strategic Investment
1.7771 of 5 stars
$5.92
+0.2%
$8.00
+35.1%
-43.0%$14.21M$62.71M-0.13N/AGap Down
High Trading Volume
MCVT
Mill City Ventures III
0 of 5 stars
$2.50
-4.6%
N/A+9.2%$15.98M$3.30M-13.163Gap Down
SFES
Safeguard Scientifics
0 of 5 stars
$0.80
flat
N/AN/A$13.38MN/A-1.31N/A
BENF
Beneficient
0 of 5 stars
$4.80
flat
N/AN/A$16.56MN/A0.00150Gap Up
MEGL
Magic Empire Global
0 of 5 stars
0.64
+6.1%
N/A-74.5%$12.97M$1.43M0.009Gap Up

Related Companies and Tools

This page (NASDAQ:LICN) was last updated on 5/2/2024 by MarketBeat.com Staff

From Our Partners